Nilotinib (AMN-107)

Catalog No.S1033

Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 210 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nilotinib (AMN-107) Chemical Structure

Nilotinib (AMN-107) Chemical Structure
Molecular Weight: 529.52

Validation & Quality Control

5 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Bcr-Abl Inhibitors with Unique Features

  • Pan Bcr-Abl Inhibitor

    Imatinib Mesylate (STI571) Multi-target inhibitor of v-Abl, c-Kit and PDGFRIC50=0.6 μM/0.1 μM/0.1 μM.

  • Most Potent Bcr-Abl Inhibitor

    GZD824 Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.

  • FDA-approved Bcr-Abl Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Bcr-Abl Inhibitor

    GZD824 Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Product Information

  • Compare Bcr-Abl Inhibitors
    Compare Bcr-Abl Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
Targets Bcr-Abl [1]
(Murine myeloid progenitor cells)
IC50 <30 nM
In vitro Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGW3c25KSzVyPUCuNFAxOTR2IN88US=>NXKzeXNHW0GQR1XS
KU812Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fPbWlEPTB;MD6wNFI1QCEQvF2=M{C1enNCVkeHUh?=
EM-2NVvBR3RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TxcmlEPTB;MD6wNFQyKM7:TR?=NVj5PIw3W0GQR1XS
LAMA-84NWHIe3pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrVTWM2OD1yLkCwOFkh|ryPM2W4enNCVkeHUh?=
MEG-01MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfQTWM2OD1yLkCwPFI5KM7:TR?=MYfTRW5ITVJ?
BV-173MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTBwMEGwPFkh|ryPM3XiTHNCVkeHUh?=
KASUMI-1NWHVXFdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnUTWM2OD1yLkCyOFE{KM7:TR?=NXnzc25wW0GQR1XS
NB7Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\a[Y5KSzVyPUCuNVM1OzlizszNMnXUV2FPT0WU
BHT-101NVrBNmpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\uTGlEPTB;MD62OFI3OyEQvF2=MmfsV2FPT0WU
CGTH-W-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnBPZRKSzVyPUCuOlQ5PyEQvF2=MXfTRW5ITVJ?
HMV-IIM2H0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHlS5pYUUN3ME2wMlc1QDd2IN88US=>MXfTRW5ITVJ?
NKM-1M1nMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PjOWlEPTB;MD65NFE2KM7:TR?=M2rmOHNCVkeHUh?=
LB2241-RCCNW\pbYwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTFwMEKyNlgh|ryPMnr1V2FPT0WU
NCI-H1703NXn3[mYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTFwMUi4O{DPxE1?MV7TRW5ITVJ?
BE-13M2Ht[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPZXpBKSzVyPUGuNlc1OTZizszNNFHFflRUSU6JRWK=
ACNMnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHxbXpVUUN3ME2xMlU2ODd5IN88US=>MnjwV2FPT0WU
A204M1:3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTBdnVuUUN3ME2xMlU4OjB3IN88US=>MnP1V2FPT0WU
HOP-62NGrqdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTFwOEKwO|ch|ryPNHrXSZlUSU6JRWK=
H9MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTIbXE{UUN3ME2yMlc{Pzl|IN88US=>NFfqOpBUSU6JRWK=
HCC1806MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTJwN{SzNlch|ryPMXTTRW5ITVJ?
NOS-1NWm3bpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInW[ItKSzVyPUKuPFcyODJizszNM2DtWXNCVkeHUh?=
RS4-11NV22N3R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrrTWM2OD1{LkmwOlI{KM7:TR?=NHzhd|JUSU6JRWK=
JARNHjoZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPpTWM2OD1{LkmyNFg1KM7:TR?=M{fyenNCVkeHUh?=
T98GMkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTNwMEGzNVMh|ryPNFTWRW9USU6JRWK=
NCI-SNU-1NXTrVGpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nUcmlEPTB;Mz60NFA6OiEQvF2=Mn;QV2FPT0WU
SK-MEL-1NXnQZlFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3HZ2VKSzVyPUOuOFMxOjlizszNNFiydFRUSU6JRWK=
L-363NWThfFZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDCNYxyUUN3ME2zMlYyOTB5IN88US=>M{ntNnNCVkeHUh?=
SW982NEHhPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTNwNkSxOlkh|ryPMke3V2FPT0WU
HT-1080MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vFPGlEPTB;Mz65NVc4PSEQvF2=MYHTRW5ITVJ?
G-402MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnpTWM2OD12LkOxNlA{KM7:TR?=M2TmNHNCVkeHUh?=
HOSMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TCbWlEPTB;ND64NFI5OiEQvF2=M4DWeHNCVkeHUh?=
SK-NEP-1NYnhNo9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEn1cIdKSzVyPUSuPFMyQTFizszNMXTTRW5ITVJ?
HAL-01MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3f0WWlEPTB;ND64PFI1OiEQvF2=NUTHNVN2W0GQR1XS
SBC-1NWPrPHJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIH6XphKSzVyPUSuPVA6ODdizszNMlXSV2FPT0WU
CTV-1NFjsOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTVwNEi5N|gh|ryPNEHmUnNUSU6JRWK=
LCLC-103HM4TqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fZSmlEPTB;NT63O|Q4OSEQvF2=M3;UfXNCVkeHUh?=
RVH-421MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3BcIJKSzVyPUWuO|c2OzZizszNMmLTV2FPT0WU
K-562MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTVwOUCzOkDPxE1?NXTldoFbW0GQR1XS
CAL-33NXLVTG5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXn4WXdkUUN3ME22MlMyOzV7IN88US=>NFT1ZY5USU6JRWK=
MDA-MB-361NFXBNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDnOIpKSzVyPU[uN|M3QTlizszNMXfTRW5ITVJ?
IGROV-1M3LsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGm1XIxKSzVyPU[uOFcyQTFizszNMl\oV2FPT0WU
NYM135XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HKO2lEPTB;Nj61N|U6QSEQvF2=MVXTRW5ITVJ?
Ramos-2G6-4C10M1TINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVP3WohbUUN3ME22MlY3QTNzIN88US=>MVrTRW5ITVJ?
HuO9MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;icmlEPTB;Nj63N|k3PCEQvF2=MljZV2FPT0WU
MS-1NYnoVVFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTdwMUG5OVMh|ryPMWXTRW5ITVJ?
RPMI-8226MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTdwMkiyPFch|ryPNFPtbYxUSU6JRWK=
HDLM-2MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTdwNECxOFkh|ryPNVzUZoF7W0GQR1XS
D-566MGMn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HabGlEPTB;Nz60O|E2PSEQvF2=Ml\3V2FPT0WU
SK-MEL-24NEjMdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFv5bHJKSzVyPUeuOlM{QTJizszNMV7TRW5ITVJ?
COLO-679NFL5WYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml2zTWM2OD15Lkm4OlcyKM7:TR?=NYr6XnVkW0GQR1XS
EW-13M2OxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rrWWlEPTB;OD6zNlA2PCEQvF2=NVXOVGdJW0GQR1XS
A388MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoewTWM2OD16LkO4OFgyKM7:TR?=NV25NosyW0GQR1XS
UM-UC-3NHPIVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPEZoxiUUN3ME24MlQ{QTV4IN88US=>NFPs[3ZUSU6JRWK=
NUGC-3NX3sXXJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\QWWlEPTB;OD61N|U5OiEQvF2=MkDPV2FPT0WU
COLO-668M1Hpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fBPGlEPTB;OD61PVQ6OSEQvF2=NYDtT|JiW0GQR1XS
MOLT-4NHXFeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWr6XphuUUN3ME24MlYzOzV|IN88US=>NYHHZVk1W0GQR1XS
D-423MGNV;kNGxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRThwOEO3OVYh|ryPMWLTRW5ITVJ?
CTB-1Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLGR2xKSzVyPUiuPFcyOjhizszNM3LYbXNCVkeHUh?=
BCPAPMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4P6OWlEPTB;OT6wNlU3OiEQvF2=M{DUVXNCVkeHUh?=
GCTNEjDR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LEb2lEPTB;OT6wPVg{OSEQvF2=NUT4UpRjW0GQR1XS
ACHNM1T3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3BTWM2OD17LkKzOlMzKM7:TR?=NV\iNWVqW0GQR1XS
KYSE-520NWW4PHBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnzfIVKSzVyPUmuN|M1QDJizszNMYrTRW5ITVJ?
LB771-HNCMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{m1Z2lEPTB;OT63OlQ6PyEQvF2=M1L1dXNCVkeHUh?=
MLMANVjq[G1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDFV5R7UUN3ME2xNE4xOTN{IN88US=>MVXTRW5ITVJ?
HEC-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4j4dGlEPTB;MUCuNlgxPCEQvF2=MXjTRW5ITVJ?
HL-60MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfFO|ZnUUN3ME2xNE43QDV|IN88US=>MoXZV2FPT0WU
A101DNHXzZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInLV2dKSzVyPUGwMlg6OjNizszNMY\TRW5ITVJ?
A2058MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nCPWlEPTB;MUCuPVI1PSEQvF2=MnuxV2FPT0WU
KARPAS-45M{fvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTFzLkC2N|Uh|ryPMlqzV2FPT0WU
697MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrSTHhWUUN3ME2xNU4zOTBzIN88US=>MWXTRW5ITVJ?
NCI-N87NEnNd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljjTWM2OD1zMT63O|MyKM7:TR?=NGD3WXpUSU6JRWK=
DSH1NGjDfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHpTWM2OD1zMT63PVU{KM7:TR?=NHnCVHpUSU6JRWK=
HLEMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTFzLki4N|kh|ryPNU\C[|I{W0GQR1XS
NCI-H720NFTDOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTF{Lk[4NFEh|ryPMVLTRW5ITVJ?
EW-3M4DrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTF{LkmzNFch|ryPMWnTRW5ITVJ?
AGSM{XPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfmZoVvUUN3ME2xN{4xOzVzIN88US=>MXjTRW5ITVJ?
ES5Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTF|LkC1NVIh|ryPNXPGXVI2W0GQR1XS
DBNE[y[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHOwTllKSzVyPUGzMlMzPTZizszNMofnV2FPT0WU
A4-FukMojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTqWXFKSzVyPUGzMlQyODJizszNMVXTRW5ITVJ?
A427MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XzSWlEPTB;MUOuOFk4OiEQvF2=NXnGd4t2W0GQR1XS
MN-60M3PPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{S4eGlEPTB;MUOuOVg1OyEQvF2=NXXBW3pDW0GQR1XS
HCC2218M3vuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTF|LkW4OVYh|ryPNHj1cJNUSU6JRWK=
MV-4-11MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vHSGlEPTB;MUOuPFE{PyEQvF2=NVy4Ump7W0GQR1XS
GI-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfZU|VKSzVyPUG0MlEyQDRizszNNILjcpBUSU6JRWK=
JVM-3NGHwbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXPeYxKSzVyPUG0MlI3PTZizszNM4XhbHNCVkeHUh?=
NCI-H2029MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2frRmlEPTB;MUSuNlczPyEQvF2=NYHFRopPW0GQR1XS
TE-12M2LDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\aOmhKSzVyPUG0MlYxPDZizszNNGjaXoFUSU6JRWK=
WM-115NF\NNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWX2c2FzUUN3ME2xOU42Pjh|IN88US=>MlOyV2FPT0WU
BB65-RCCNHvtOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXseYFKSzVyPUG2MlAzPDFizszNM1noUXNCVkeHUh?=
NCI-H1693NInXcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1G5cWlEPTB;MU[uN|gxOiEQvF2=MV7TRW5ITVJ?
KARPAS-299NV3JOphFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTF4Lk[yNFMh|ryPNEnDb3dUSU6JRWK=
UACC-257MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnJTWM2OD1zNz6wOVgzKM7:TR?=MnfEV2FPT0WU
RKONIm4ZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvmelhmUUN3ME2xO{43PDN|IN88US=>NYHrNog5W0GQR1XS
HT-29M1W4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33CSGlEPTB;MUeuO|g5QSEQvF2=MV;TRW5ITVJ?
ES7NHrvTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1:5UWlEPTB;MUiuNVEzOiEQvF2=M4G0Z3NCVkeHUh?=
DELM4r1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTF6LkOxO|Ih|ryPMXLTRW5ITVJ?
BT-549NV24Z3ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPkN29KSzVyPUG4MlQxQTJizszNMXHTRW5ITVJ?
NCI-H1755M{Tudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnOWnVKSzVyPUG4MlU4OjNizszNM2i2XnNCVkeHUh?=
HCE-TMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnSTWM2OD1zOD64N|QyKM7:TR?=Ml;IV2FPT0WU
LU-139MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYW1RVZKUUN3ME2xPU4xPDV6IN88US=>NXnOfGg2W0GQR1XS
ECC10NH7lTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTF7LkK0O|Uh|ryPNEC5XlVUSU6JRWK=
769-PNYjTNHlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTsTnE{UUN3ME2xPU43OzN3IN88US=>MYTTRW5ITVJ?
BALL-1MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTJ[pdwUUN3ME2xPU43Pzd3IN88US=>NUnBeJU3W0GQR1XS
LXF-289NVnaSJFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWC4dIRMUUN3ME2xPU45QTd7IN88US=>NXHib4M{W0GQR1XS
TYK-nuNFfjUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLPO2tqUUN3ME2xPU46OzF3IN88US=>MoixV2FPT0WU
NCI-H630NEnSXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmKxTWM2OD1zOT65N|c5KM7:TR?=MWLTRW5ITVJ?
EW-18MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XRTWlEPTB;MkCuN|gxOiEQvF2=NHTsN|JUSU6JRWK=
KYSE-150MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnBTWM2OD1{MD63NFQ4KM7:TR?=MkLrV2FPT0WU
LOXIMVIM4TXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DEUGlEPTB;MkCuO|U5PiEQvF2=MlLIV2FPT0WU
HuP-T3NGDCbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDQeJVKSzVyPUKxMlA5PTJizszNNWTn[HFxW0GQR1XS
MFE-280NUC0R5VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHLUJBKSzVyPUKxMlU3PzlizszNNH3hcIdUSU6JRWK=
SK-OV-3MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHMN3pKSzVyPUKxMlg1ODhizszNNH31TplUSU6JRWK=
QIMR-WILNY\WXIRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDHWopJUUN3ME2yNk4xPDd6IN88US=>Mn[5V2FPT0WU
NCI-H69NVKzeYYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlWyTWM2OD1{Mj60Nlk6KM7:TR?=MmjNV2FPT0WU
TE-5M33DSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\zTWM2OD1{Mj60PVY2KM7:TR?=Mm\mV2FPT0WU
NCI-H1993M33oeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nGN2lEPTB;MkKuOFk4OSEQvF2=MnfNV2FPT0WU
NCI-H1092MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzucYtKSzVyPUKzMlI5PDNizszNMmniV2FPT0WU
RH-1M{TrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPMTWM2OD1{Mz61N|U4KM7:TR?=MlPpV2FPT0WU
DBTRG-05MGMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXCdoxKSzVyPUKzMlg1PzJizszNMo\QV2FPT0WU
Mo-TMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLx[npFUUN3ME2yN{46KM7:TR?=M3TwW3NCVkeHUh?=
HD-MY-ZM3XvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHMfIdWUUN3ME2yOE4zOzZ{IN88US=>MY\TRW5ITVJ?
NCI-H2342NVPsT5Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTJ2Lk[3Olch|ryPMVTTRW5ITVJ?
C32MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\xTWM2OD1{ND65OVc3KM7:TR?=MXzTRW5ITVJ?
HTC-C3M3LFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\5TGlEPTB;MkWuN|U4PyEQvF2=NEHDUplUSU6JRWK=
NCI-H358NYDMfpRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJ3LkO5OFMh|ryPMl7aV2FPT0WU
CAL-85-1NYjUT|dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jwTGlEPTB;MkWuOFU4PyEQvF2=NVLyOJZlW0GQR1XS
HT-1197NXfSfXY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDFPIg{UUN3ME2yOU42OzF7IN88US=>NEnnc2JUSU6JRWK=
A172MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTJ3LkexN|Yh|ryPM2LNO3NCVkeHUh?=
SW1573Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWez[mloUUN3ME2yOU44Pzh3IN88US=>NHnTb4VUSU6JRWK=
EW-24M2TVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfKSohKSzVyPUK1Mlk3OiEQvF2=MnfzV2FPT0WU
SK-MEL-2M4Xufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TQTmlEPTB;Mk[uNFMyOiEQvF2=NWnlWoZOW0GQR1XS
LU-65MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrDSHhKSzVyPUK2MlA1PTJizszNMWTTRW5ITVJ?
KMOE-2NGHTdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HhbWlEPTB;Mk[uNFkyPSEQvF2=NUS2U4R1W0GQR1XS
H-EMC-SSNH:3fYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2j5NWlEPTB;Mk[uOFEyPCEQvF2=MorZV2FPT0WU
H4MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjlTWM2OD1{Nj60NlQ{KM7:TR?=NWLER|lQW0GQR1XS
DU-4475MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3m2SGlEPTB;MkeuNVg4OiEQvF2=MX\TRW5ITVJ?
HCT-116M{TuVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTJ5LkSzOFkh|ryPMVLTRW5ITVJ?
MSTO-211HNX3HOFVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTJ5Lk[yOVUh|ryPMmjDV2FPT0WU
NCI-H292M{C2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3kUZJKSzVyPUK3Mlk3OTdizszNNITIPHNUSU6JRWK=
NCI-H446NIrQPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;HTWM2OD1{OD6yNVA2KM7:TR?=M1ixSnNCVkeHUh?=
NCI-H2009M2PnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnTS4hKSzVyPUK5MlE1OzFizszNM1fGZnNCVkeHUh?=
MHH-ES-1M2fBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnmWldvUUN3ME2yPU4{Pjh3IN88US=>NVK5XndRW0GQR1XS
TI-73MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTJ7LkSwNFEh|ryPMkTvV2FPT0WU
NCI-H2228MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmGzTWM2OD1{OT60OVgh|ryPNEeyfpNUSU6JRWK=
MHH-PREB-1NW\KU5U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnToTWM2OD1{OT61OVA2KM7:TR?=MWjTRW5ITVJ?
ChaGo-K-1NVP2cHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTJ7Lk[wPVch|ryPMXnTRW5ITVJ?
KY821M1;aTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkP4TWM2OD1{OT62OFM{KM7:TR?=NYG5cVhtW0GQR1XS
NCI-H209MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;kTWM2OD1{OT64N|Y3KM7:TR?=M2THcnNCVkeHUh?=
NBsusSRNFTKV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDNTWM2OD1{OT65PVA1KM7:TR?=NFrtboRUSU6JRWK=
NCI-H1304NXroXXpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDX[ZduUUN3ME2zNE42PzF4IN88US=>Ml7YV2FPT0WU
NB14NFrEVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTNzLkC0OFYh|ryPMn3CV2FPT0WU
HCC1419NFfWcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnYcoVKSzVyPUOxMlI1KM7:TR?=MYHTRW5ITVJ?
KG-1M4Dmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTNzLke0Nlkh|ryPM3rZXXNCVkeHUh?=
A2780MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlP5TWM2OD1|MT64N|U5KM7:TR?=M3jDXnNCVkeHUh?=
NCI-H28MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGG2fItKSzVyPUOxMlk5PjFizszNM2S5SnNCVkeHUh?=
C2BBe1NITTeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDYcGhKSzVyPUOyMlI3OzRizszNNXT0foxlW0GQR1XS
VA-ES-BJMnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTaV29FUUN3ME2zNk4{OSEQvF2=M2frOHNCVkeHUh?=
SBC-5NE[0TnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTN{Lki1NVEh|ryPNGjLbYtUSU6JRWK=
OVCAR-4NYj2N4h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTN|LkS4OFgh|ryPNF;mc4pUSU6JRWK=
COR-L88M4XrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPaTWM2OD1|ND6wO|QyKM7:TR?=M3n1O3NCVkeHUh?=
SW954NVqzcmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTN2LkC3OVIh|ryPMV7TRW5ITVJ?
COLO-684NYO1empyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fMfGlEPTB;M{SuN|QxPCEQvF2=NXvzRWtGW0GQR1XS
HCC70MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17VRmlEPTB;M{SuPVUyPCEQvF2=NWfBTXZbW0GQR1XS
NCI-H1770MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vPPGlEPTB;M{SuPVYyKM7:TR?=MWPTRW5ITVJ?
NCI-H1666NG\LXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTN3LkiyOVMh|ryPMoD0V2FPT0WU
YH-13NWLNRm5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rwV2lEPTB;M{WuPVIh|ryPMn7mV2FPT0WU
DJM-1M1nYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTN4LkiwOFkh|ryPNXjFR2g4W0GQR1XS
KNS-62MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HKeWlEPTB;M{[uPVQ{QCEQvF2=NHHQdlhUSU6JRWK=
SK-MEL-30M3T6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fRZ2lEPTB;M{euPFc{PyEQvF2=NFmzcVVUSU6JRWK=
SJRH30MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml63TWM2OD1|OD63N|QyKM7:TR?=M{HsS3NCVkeHUh?=
GP5dNIPB[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLaTWM2OD1|OD64OlU{KM7:TR?=M3\KXXNCVkeHUh?=
SW1116NFrRWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{H6emlEPTB;M{muNlgxPSEQvF2=MljhV2FPT0WU
COLO-800MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;tTWM2OD1|OT6zOlM5KM7:TR?=NUjWOXg1W0GQR1XS
RDMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnCOFVKSzVyPUO5MlUzPThizszNM1;RPXNCVkeHUh?=
NCI-SNU-5MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTN7Lk[5NVYh|ryPM37YUnNCVkeHUh?=
HuO-3N1MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fiV2lEPTB;NECuNVA5KM7:TR?=NH;GOoNUSU6JRWK=
SK-UT-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYP0e4pWUUN3ME20NE42Pjd2IN88US=>MUPTRW5ITVJ?
SK-MEL-3M33jcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHyTWM2OD12MD61PVMzKM7:TR?=NFfVU2lUSU6JRWK=
SK-MEL-28M2O0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfzSnJzUUN3ME20NE43PDN3IN88US=>NInYN|NUSU6JRWK=
SCC-4MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\2TWM2OD12MT6yNVM4KM7:TR?=Mmm0V2FPT0WU
no-11MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHofnRKSzVyPUSxMlc{PTRizszNNIjmT|BUSU6JRWK=
HT-144MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPrS|VKSzVyPUSyMlA2PjdizszNNWDXNI5XW0GQR1XS
MFM-223NVTnWpk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\yZmo{UUN3ME20Nk41ODJizszNMoDQV2FPT0WU
ONS-76M2L1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTmTWM2OD12Mj64NFE5KM7:TR?=NV\lOY9WW0GQR1XS
ES8NWm2O5NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTR|LkO2PVgh|ryPMm\iV2FPT0WU
T-24NWjJ[2JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrUeWNKSzVyPUSzMlQ{PjlizszNMWfTRW5ITVJ?
GAMGNHfORpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHpe3k4UUN3ME20N{41PTF5IN88US=>NFntd3NUSU6JRWK=
LU-135NIjk[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVz1PVRUUUN3ME20OE4xQTJ|IN88US=>MV3TRW5ITVJ?
HCC1187M{T5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHWXppKSzVyPUS0MlgzPjJizszNMUjTRW5ITVJ?
TE-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTR3LkG2OVQh|ryPNXnRUJVFW0GQR1XS
J-RT3-T3-5M3jyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLjTWM2OD12NT60N|E2KM7:TR?=NH;nbYZUSU6JRWK=
GI-ME-NNIiyd|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DacGlEPTB;NEWuPFk2OiEQvF2=MX7TRW5ITVJ?
D-392MGMnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHVTWM2OD12NT65NlU3KM7:TR?=NGDRXmZUSU6JRWK=
KALS-1NFrVUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LBbmlEPTB;NE[uO|I2PyEQvF2=MmG1V2FPT0WU
MMAC-SFNVfhdIp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVz5fpZHUUN3ME20Ok46QTV{IN88US=>NUTGNo9KW0GQR1XS
HSC-3MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDnXIpuUUN3ME20O{4{PjB6IN88US=>MVTTRW5ITVJ?
KM-H2NHrLeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Pv[mlEPTB;NEeuOlAxPyEQvF2=NV3U[VdOW0GQR1XS
LoVoNGnWUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjIOY9KSzVyPUS4MlExODJizszNNWfJRnNCW0GQR1XS
NCI-H510ANYPPPHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PwbGlEPTB;NEiuNVg4OSEQvF2=Mo\NV2FPT0WU
EW-11NHfjTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jXeGlEPTB;NEiuNlM1QCEQvF2=MnvwV2FPT0WU
HCC2998M1TKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;2c2VKSzVyPUS4MlYzOzZizszNMXTTRW5ITVJ?
J82NF3oe3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTCNJRjUUN3ME20PE44OjR{IN88US=>M3vocnNCVkeHUh?=
ML-2MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjSUJBJUUN3ME20PU41PjB3IN88US=>NH:2T5RUSU6JRWK=
NCI-H2030MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjtb3IxUUN3ME20PU44OTF5IN88US=>NXfG[ZRiW0GQR1XS
NCI-H1792NF3JVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\zOnVZUUN3ME20PU45PTF6IN88US=>NV;mdZFHW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]
Features A selective inhibitor of native and mutant Bcr-Abl.

Protocol(Only for Reference)

Cell Assay: [4]

Cell lines Human primary Schwann and schwannoma cells
Concentrations 1-10 μM
Incubation Time 72 hours
Method Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.

Animal Study: [6]

Animal Models Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
Formulation 10% NMP-90% PEG300, PEG300
Dosages 75 mg/kg, 100 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Weisberg E, et al. Blood. 2007, 109(5), 2112-2120.

[2] Liu Y, et al. J Hepatol. 2011, 55(3), 612-625.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02709083 Not yet recruiting Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia Emory University December 2016 Phase 2
NCT01887522 Recruiting Refractory Low-grade Gliomas|Recurrent Low-grade Gliomas Gustave Roussy, Cancer Campus, Grand Paris|Innovative The  ...more Gustave Roussy, Cancer Campus, Grand Paris|Innovative Therapies For Children with Cancer Consortium June 2016 Phase 2
NCT02774512 Not yet recruiting Colon Cancer Institut Bergonié|Novartis Pharmaceuticals May 2016 Phase 0
NCT02611492 Recruiting Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia Assistance Publique - Hôpitaux de Paris April 2016 Phase 3
NCT02602314 Not yet recruiting Chronyc Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto March 2016 Phase 4

view more

Chemical Information

Download Nilotinib (AMN-107) SDF
Molecular Weight (MW) 529.52
Formula

C28H22F3N7O

CAS No. 641571-10-0
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 27 mg/mL (50.98 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 3mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcr-Abl Products

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • Imatinib Mesylate (STI571)

    Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

  • Ponatinib (AP24534)

    Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

  • Bafetinib (INNO-406)

    Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

    Features:Dual Bcr-Abl/Lyn inhibitor.

  • Degrasyn (WP1130)

    Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

    Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.

  • DCC-2036 (Rebastinib)

    DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

    Features:A conformational control inhibitor of Abl1 and T315I Abl1.

  • GZD824 Dimesylate

    GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

  • GNF-2

    GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Recently Viewed Items

Tags: buy Nilotinib (AMN-107) | Nilotinib (AMN-107) supplier | purchase Nilotinib (AMN-107) | Nilotinib (AMN-107) cost | Nilotinib (AMN-107) manufacturer | order Nilotinib (AMN-107) | Nilotinib (AMN-107) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us